Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91,258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Yue D, et al. Among authors: chen q, chen c, chen h. Lancet Respir Med. 2024 Nov 21:S2213-2600(24)00269-8. doi: 10.1016/S2213-2600(24)00269-8. Online ahead of print. Lancet Respir Med. 2024. PMID: 39581197
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Yue D, et al. Among authors: chen c, chen h. Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24. Lancet Respir Med. 2018. PMID: 30150014 Clinical Trial.
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Ni J, Huang M, Zhang L, Wu N, Bai CX, Chen LA, Liang J, Liu Q, Wang J, Wu YL, Zhang FC, Zhang SY, Chen C, Chen J, Fang WT, Gao SG, Hu J, Jiang T, Li SQ, Li HC, Liao YD, Liu Y, Liu DR, Liu HX, Liu JY, Liu LX, Wang MZ, Wang CL, Yang F, Yang Y, Zhang LJ, Zhi XY, Zhong WZ, Guan YZ, Guo XX, He CX, Li SL, Li Y, Liang NX, Lu FL, Lv C, Lv W, Si XY, Tan FW, Wang HP, Wang JS, Yan S, Yang HX, Zhu HJ, Zhuang JL, Zhuo ML. Ni J, et al. Among authors: chen j, chen la, chen c. Thorac Cancer. 2021 May;12(9):1469-1488. doi: 10.1111/1759-7714.13942. Epub 2021 Mar 30. Thorac Cancer. 2021. PMID: 33787090 Free PMC article.
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer].
Ni J, Huang M, Zhang L, Wu N, Bai C, Chen L, Liang J, Liu Q, Wang J, Wu Y, Zhang F, Zhang S, Chen C, Chen J, Fang W, Gao S, Hu J, Jiang T, Li S, Li H, Liao Y, Liu Y, Liu D, Liu H, Liu J, Liu L, Wang M, Wang C, Yang F, Yang Y, Zhang L, Zhi X, Zhong W, Guan Y, Guo X, He C, Li S, Li Y, Liang N, Lu F, Lv C, Lv W, Si X, Tan F, Wang H, Wang J, Yan S, Yang H, Zhu H, Zhuang J, Zhuo M. Ni J, et al. Among authors: chen j, chen l, chen c. Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):141-160. doi: 10.3779/j.issn.1009-3419.2021.101.06. Zhongguo Fei Ai Za Zhi. 2021. PMID: 33819964 Free PMC article. Chinese.
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
He J, Su C, Liang W, Xu S, Wu L, Fu X, Zhang X, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Zhou C. He J, et al. Among authors: chen q, chen c. Lancet Respir Med. 2021 Sep;9(9):1021-1029. doi: 10.1016/S2213-2600(21)00134-X. Epub 2021 Jul 21. Lancet Respir Med. 2021. PMID: 34280355 Clinical Trial.
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Zhang Z, Zhang B, Wang C. Yue D, et al. Among authors: chen c, chen h. J Clin Oncol. 2022 Dec 1;40(34):3912-3917. doi: 10.1200/JCO.22.00428. Epub 2022 Aug 26. J Clin Oncol. 2022. PMID: 36027483 Clinical Trial.
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
Qiu B, Cai K, Chen C, Chen J, Chen KN, Chen QX, Cheng C, Dai TY, Fan J, Fan Z, Hu J, Hu WD, Huang YC, Jiang GN, Jiang J, Jiang T, Jiao WJ, Li HC, Li Q, Liao YD, Liu HX, Liu JF, Liu L, Liu Y, Long H, Luo QQ, Ma HT, Mao NQ, Pan XJ, Tan F, Tan LJ, Tian H, Wang D, Wang WX, Wei L, Wu N, Wu QC, Xiang J, Xu SD, Yang L, Zhang H, Zhang L, Zhang P, Zhang Y, Zhang Z, Zhu K, Zhu Y, Um SW, Oh IJ, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Sasada S, Uchino J, Sugimura H, Dermime S, Cappuzzo F, Rizzo S, Cho WC, Crucitti P, Longo F, Lee KY, De Ruysscher D, Vanneste BGL, Furqan M, Sieren JC, Yendamuri S, Merrell KW, Molina JR, Metro G, Califano R, Bongiolatti S, Provencio M, Hofman P, Gao S, He J. Qiu B, et al. Among authors: chen j, chen kn, chen c, chen qx. Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634. Transl Lung Cancer Res. 2021. PMID: 34733623 Free PMC article. Review. No abstract available.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Among authors: chen kn, chen c. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Zeng J, Mao WM, Chen QX, Luo TB, Wu YL, Zhou Q, Yang XN, Yan HH, Zhong WZ, Wang Q, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT. Zeng J, et al. Among authors: chen kn, chen c, chen qx. Lung Cancer. 2020 Dec;150:164-171. doi: 10.1016/j.lungcan.2020.09.027. Epub 2020 Oct 8. Lung Cancer. 2020. PMID: 33186858 Clinical Trial.
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Zhong WZ, et al. Among authors: chen kn, chen c. J Clin Oncol. 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. Epub 2020 Dec 17. J Clin Oncol. 2021. PMID: 33332190 Free PMC article. Clinical Trial.
91,258 results
You have reached the last available page of results. Please see the User Guide for more information.